Is it safe for a patient with Attention Deficit Hyperactivity Disorder (ADHD) to take Vyvanse (lisdexamfetamine) and Adderall (amphetamine and dextroamphetamine) together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Taking Vyvanse and Adderall Together: Safety Assessment

No, it is not safe to take Vyvanse and Adderall together—both are amphetamine-based stimulants that work through identical mechanisms, and combining them creates excessive amphetamine exposure with significantly increased cardiovascular risks and no therapeutic benefit. 1

Why This Combination Is Dangerous

Both medications are amphetamine-based stimulants that inhibit reuptake and promote release of dopamine and norepinephrine through the same mechanism. 1 The key difference is that Vyvanse is a prodrug requiring conversion to active d-amphetamine in the body, while Adderall contains immediately active amphetamine salts (75% dextroamphetamine and 25% levoamphetamine). 1 Taking both simultaneously is essentially doubling up on the same medication class, creating an overdose scenario rather than complementary therapy.

Cardiovascular Risks of Excessive Amphetamine Exposure

  • Stimulant medications cause small but statistically significant increases in blood pressure and heart rate at therapeutic doses. 2
  • Amphetamine overdose causes hyperactivity, hyperthermia, tachycardia, tachypnea, mydriasis, tremors, and seizures. 3
  • α-Adrenergic stimulation causes vasoconstriction and increased total peripheral resistance, while β-adrenergic receptor stimulation leads to increased heart rate and stroke volume. 3
  • Adults with ADHD taking stimulants are at risk for rare but serious cardiovascular events including acute myocardial infarction, arrhythmia, and cardiomyopathy. 4
  • Both medications should be avoided in patients with uncontrolled hypertension, coronary artery disease, tachyarrhythmias, or active substance use disorders. 1

The Correct Approach: Switching, Not Combining

If Vyvanse is not providing adequate symptom control, the appropriate strategy is a direct switch to Adderall, not adding it on top. 1

Switching Protocol

  • Stop Vyvanse and start Adderall the next day at an equivalent dose with no washout period required because both have similar mechanisms and short half-lives. 1
  • Approximate dose conversions: 30 mg Vyvanse ≈ 10 mg Adderall; 50 mg Vyvanse ≈ 15-20 mg Adderall; 70 mg Vyvanse ≈ 20-30 mg Adderall. 1
  • For Adderall IR: Start with 5-10 mg once or twice daily (morning and midday), titrate in 5-10 mg increments weekly as needed. 1
  • For Adderall XR: Start with 10-20 mg once daily in the morning, titrate in 5-10 mg increments weekly up to maximum 50 mg daily. 1

Monitoring During Transition

  • Monitor closely during the first 1-2 weeks for decreased appetite, insomnia, irritability, headache, upper abdominal pain, and cardiovascular effects such as blood pressure and heart rate changes. 1
  • Assess ADHD symptom improvement throughout the day and watch for rebound symptoms, particularly with shorter-acting formulations. 1

Common Pitfalls to Avoid

  • Never combine two amphetamine-based stimulants—this is not standard practice and represents a medication error, not optimization. 1
  • Do not assume that combining stimulants will provide better coverage than properly titrating a single agent to optimal dose. 5
  • Avoid using stimulants in patients with personal or family history of cardiovascular disease without careful cardiovascular assessment. 2
  • Both are Schedule II controlled substances with abuse potential, though Vyvanse's prodrug formulation theoretically confers lower abuse liability. 1, 6

Alternative Strategies for Inadequate Response

If a single stimulant at optimal doses is not providing adequate symptom control:

  • Consider switching to methylphenidate-based medications (Ritalin, Concerta) as they have different mechanisms and side effect profiles. 1
  • Approximately 40% of patients respond to both amphetamine and methylphenidate classes, while 40% respond to only one. 5
  • Consider adding adjunctive non-stimulant medications like guanfacine extended-release for residual symptoms rather than adding a second stimulant. 5
  • Evaluate for comorbid conditions (depression, anxiety) that may require separate treatment with SSRIs or other agents. 5

References

Guideline

Switching from Vyvanse to Adderall for ADHD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Adderall® (amphetamine-dextroamphetamine) toxicity.

Topics in companion animal medicine, 2013

Guideline

Medication Options for Managing Both Mood Symptoms and ADHD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Lisdexamfetamine dimesylate for childhood ADHD.

Drugs of today (Barcelona, Spain : 1998), 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.